Breakthrough combo targets aggressive stomach cancers
NCT ID NCT06206733
Summary
This large Phase 3 trial is testing whether adding a new drug called ASKB589 to standard chemotherapy and immunotherapy works better for advanced stomach or gastroesophageal cancer. The study is for patients whose cancer tests positive for a specific protein called CLDN18.2 and who haven't had prior treatment for their advanced disease. Researchers will compare how long patients live without their cancer getting worse between the new combination and the current standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing cancer hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.